Leelyn Smith LLC Raises Stake in Merck & Co., Inc. (NYSE:MRK)

Leelyn Smith LLC lifted its stake in shares of Merck & Co., Inc. (NYSE:MRKFree Report) by 3.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 39,122 shares of the company’s stock after acquiring an additional 1,286 shares during the period. Leelyn Smith LLC’s holdings in Merck & Co., Inc. were worth $3,892,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of MRK. State Street Corp raised its stake in Merck & Co., Inc. by 1.3% during the third quarter. State Street Corp now owns 119,026,412 shares of the company’s stock worth $13,606,360,000 after purchasing an additional 1,536,474 shares during the period. Wellington Management Group LLP increased its holdings in shares of Merck & Co., Inc. by 4.6% during the 3rd quarter. Wellington Management Group LLP now owns 75,809,383 shares of the company’s stock worth $8,608,914,000 after buying an additional 3,327,404 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Merck & Co., Inc. by 3.7% during the 3rd quarter. Geode Capital Management LLC now owns 59,155,004 shares of the company’s stock valued at $6,696,060,000 after buying an additional 2,134,296 shares during the period. Bank of New York Mellon Corp lifted its holdings in Merck & Co., Inc. by 29.7% in the fourth quarter. Bank of New York Mellon Corp now owns 24,213,537 shares of the company’s stock valued at $2,408,763,000 after acquiring an additional 5,550,824 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Merck & Co., Inc. by 7.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 20,125,171 shares of the company’s stock worth $2,002,052,000 after acquiring an additional 1,317,878 shares during the period. Institutional investors and hedge funds own 76.07% of the company’s stock.

Insider Buying and Selling at Merck & Co., Inc.

In related news, insider Cristal N. Downing sold 2,361 shares of the company’s stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $88.76, for a total value of $209,562.36. Following the completion of the transaction, the insider now directly owns 7,085 shares of the company’s stock, valued at $628,864.60. This represents a 24.99 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Inge G. Thulin acquired 2,833 shares of the business’s stock in a transaction on Thursday, February 6th. The shares were bought at an average cost of $88.25 per share, for a total transaction of $250,012.25. Following the acquisition, the director now owns 2,933 shares of the company’s stock, valued at $258,837.25. This represents a 2,833.00 % increase in their position. The disclosure for this purchase can be found here. 0.09% of the stock is owned by insiders.

Wall Street Analyst Weigh In

MRK has been the topic of a number of research analyst reports. Truist Financial restated a “hold” rating and issued a $110.00 target price (down previously from $130.00) on shares of Merck & Co., Inc. in a research report on Wednesday, January 8th. TD Cowen lowered shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and reduced their price objective for the company from $121.00 to $100.00 in a report on Monday, February 10th. TD Securities lowered shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and lowered their target price for the stock from $121.00 to $100.00 in a research note on Monday, February 10th. Morgan Stanley reduced their price target on shares of Merck & Co., Inc. from $113.00 to $106.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 5th. Finally, BMO Capital Markets decreased their price objective on shares of Merck & Co., Inc. from $105.00 to $96.00 and set a “market perform” rating on the stock in a report on Wednesday, February 5th. Eleven analysts have rated the stock with a hold rating, nine have assigned a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $117.12.

Check Out Our Latest Report on MRK

Merck & Co., Inc. Stock Performance

Shares of Merck & Co., Inc. stock opened at $94.84 on Tuesday. The business has a 50-day simple moving average of $93.47 and a 200-day simple moving average of $101.62. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.15 and a current ratio of 1.36. Merck & Co., Inc. has a one year low of $81.04 and a one year high of $134.63. The company has a market cap of $239.56 billion, a PE ratio of 14.09, a P/E/G ratio of 0.77 and a beta of 0.35.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The company reported $1.72 EPS for the quarter, missing the consensus estimate of $1.85 by ($0.13). Merck & Co., Inc. had a return on equity of 45.35% and a net margin of 26.67%. The firm had revenue of $15.62 billion for the quarter, compared to analyst estimates of $15.51 billion. During the same quarter last year, the firm earned $0.03 EPS. The company’s revenue was up 6.8% on a year-over-year basis. On average, equities research analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. announced that its Board of Directors has approved a stock buyback program on Tuesday, January 28th that authorizes the company to buyback $10.00 billion in outstanding shares. This buyback authorization authorizes the company to purchase up to 4.1% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, April 7th. Investors of record on Monday, March 17th will be issued a $0.81 dividend. This represents a $3.24 annualized dividend and a yield of 3.42%. The ex-dividend date of this dividend is Monday, March 17th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 48.14%.

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

See Also

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.